The AstraZeneca PLC ADR AZN advanced 1.42% to $77.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.61% to ...

The AstraZeneca PLC ADR AZN slid 2.30% to $74.24 Tuesday, on what proved to be an all-around dismal trading session for the ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Within the Medical – Pharmaceuticals industry, PFE is ranked #35 out of 152 stocks. Headquartered in Cambridge, United Kingdom, AZN is a biopharmaceutical company focusing on discovering, developing, ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase “defensive ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best global stocks to buy according to hedge funds. The United States has long been a magnet ...

FibroGen sells its China unit to AstraZeneca for about $160M, strengthening its cash position and extending its financial runway into 2027. AstraZeneca gains full rights to roxadustat in China ...

In its fourth quarter 2024 investor letter, Baron Health Care Fund emphasized stocks such as AstraZeneca PLC (NASDAQ:AZN). AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that ...

Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...